Hospital Genral Universitario e Instituto de Investigación Sanitaria Gregorio Marañón. UCM., Madrid, España.
Hospital General Universitario e Instituto de Investigación Gregorio Marañón. UCM., Madrid, España.
Rev Neurol. 2024 May 1;78(9):265-268. doi: 10.33588/rn.7809.2023306.
We present a narcolepsy type 1 patient that develop an autoimmune encephalitis post vaccine and/or a SARS-CoV-2 infection.
At 23 years old, the patient was referred to the emergency room with difficult speaking, headache and tremor followed by changes in behavior, autonomic dysfunction, right focal motor seizure and lethargy. He has received seven weeks before mRNA-1273 (Moderna) vaccine followed by a SARS-CoV-2 infection four weeks after vaccination (positive antigen test).
The neurological examination was normal (visual fields, cranial nerves, motor, sensory and reflexes). Nasopharyngeal swab polymerase chain reaction (PCR) testing for COVID-19 was negative. Cerebrospinalfluid (CSF) had highly elevated protein and lymphocytic pleocytosis. CSF bacterial and fungal cultures for viral infections were negative. Brain magnetic resonance imaging (MRI) showed no abnormality on the non-enhanced sequences but the diffusion weighted imaging showed restricted diffusion with high signal on the left hemisphere mainly in the cerebral cortex with a gyro morphology, patched distribution with involvement of the temporal and frontal lobes. Chest, abdomen and pelvis computed tomography; pelvic and scrotum ultrasound, showed no malignancy. Onconeural antibodies were negative. The patient was treated with plasmapheresis and corticosteroids with a good clinical outcome and near complete resolution of the MRI abnormalities.
The patient fulfilled the diagnostic criteria for autoimmune encephalitis with subacute onset. COVID-19 infection and vaccination could constitute a risk in a patient with narcolepsy as in this case and, could help to provide better understanding of the implication of immune-mediated processes in the pathophysiology of the diseases.
我们报告了 1 例 1 型发作性睡病患者在接种疫苗后/或感染 SARS-CoV-2 后发生自身免疫性脑炎。
23 岁时,患者因言语困难、头痛和震颤被紧急转至急诊室,随后出现行为改变、自主神经功能障碍、右侧局灶性运动性癫痫发作和昏睡。他在接种 mRNA-1273(Moderna)疫苗前 7 周,接种疫苗后 4 周感染 SARS-CoV-2(抗原检测阳性)。
神经系统检查正常(视野、颅神经、运动、感觉和反射)。鼻咽拭子聚合酶链反应(PCR)检测 COVID-19 为阴性。脑脊液(CSF)蛋白高度升高且淋巴细胞增多。CSF 细菌和真菌培养以及病毒感染均为阴性。脑磁共振成像(MRI)显示非增强序列无异常,但弥散加权成像显示左半球弥散受限,信号高,主要在大脑皮质,呈回旋形,补丁状分布,累及颞叶和额叶。胸部、腹部和骨盆计算机断层扫描;骨盆和阴囊超声检查未发现恶性肿瘤。神经肿瘤抗体阴性。患者接受了血浆置换和皮质类固醇治疗,临床结果良好,MRI 异常几乎完全缓解。
该患者符合自身免疫性脑炎的亚急性起病诊断标准。在 1 型发作性睡病患者中,COVID-19 感染和疫苗接种可能构成风险,就像本例一样,这有助于更好地了解免疫介导过程在疾病病理生理学中的意义。